Lexicon Pharmaceuticals Inc $1.60

down -0.15


23/4/2014 05:20 PM  |  NASDAQ : LXRX  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get LXRX Trend Analysis - it has underperformed the S&P 500 by 49%

Partner Headlines

  1. Mid-Morning Market Update: Markets Open Higher; Citigroup Results Beat ...

    Benzinga
  2. Morning Market Movers

    Benzinga
  3. US Stock Futures Flat; Citigroup Earnings In Focus

    Benzinga
  4. Benzinga's Top Initiations

    Benzinga
  5. UPDATE: Bank of America Initiates Underperform On Lexicon Pharmaceuticals, ...

    Benzinga
  6. Benzinga's Top #PreMarket Losers

    Benzinga
  7. Lexicon Phase 2 Study Of LX1033 In IBS-d Shows Differences Between Placebo ...

    Benzinga
  8. Benzinga's Top Pre-Market Losers

    Benzinga
  9. Lexicon Pilot Study of Telotristat Etiprate In Ulcerative Colitis Achieves ...

    Benzinga
  10. Market Wrap For Tuesday, October 1: Government Down, Markets Up

    Benzinga
  11. Mid-Afternoon Market Update: Markets Remain Up As Government Shutdown Continues

    Benzinga
  12. Mid-Day Market Update: US Stocks Extend Gains; Lexicon Shares Surge

    Benzinga
  13. Mid-Morning Market Update: Markets Rise; Walgreen Earnings Surge 86%

    Benzinga
  14. Morning Market Movers

    Benzinga
  15. Benzinga's Top Pre-Market Gainers

    Benzinga
  16. Lexicon Pharma Reports Results from Trial of LX4211, Says Met Primary Goal, ...

    Benzinga
  17. Lexicon Pharmaceuticals Provides Clinical Pipeline Update

    Benzinga
  18. Stocks Surge as Fiscal Cliff Deal Appears Close

    Benzinga
  19. Mid-Day Market Update: Political Indecision Looms, Yet Markets Rise

    Benzinga
  20. Mid-Morning Market Update: Markets Rise Ahead of Fiscal Cliff, Cott Falls

    Benzinga
  21. Mid-Morning Market Update: Caribou Bought Out; Clearwire Plummets

    Benzinga
  22. Lexicon Pharma Shares Rise Following FDA Fast Track Designation for LX1 ...

    Benzinga
  23. Lexicon Genetics Inc. Reports Operating Results (10-Q)

    GuruFocus
  24. Lexicon Pharma Says Primary Efficacy Endpoint Was Achieved

    Benzinga
  25. Lexicon Prices 17.5M Shares At $2.25 per Share

    Benzinga
  26. Lexicon Announces Proposed Common Stock Offering

    Benzinga
  27. Benzinga's Top Pre-Market Gainers

    Benzinga
  28. Benzinga's Top Pre-Market Gainers

    Benzinga
  29. A Peek Into The Market Before The Trading Starts

    Benzinga
  30. A Peek Into The Market Before The Trading Starts

    Benzinga
  31. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies

    Benzinga
  32. Lexicon Genetics Inc. Reports Operating Results (10-Q)

    GuruFocus
  33. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second ...

    Benzinga
  34. A Peek Into The Market Before The Trading Starts

    Benzinga
  35. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients ...

    Benzinga
  36. SBA Communications Corporation, The Ryland Group Among Stocks Hitting 52-Week ...

    FoxBusiness
  37. Teva Pharmaceutical Industries, Constellation Brands Among Stocks Up on ...

    FoxBusiness
  38. Benzinga's Top Pre-Market Gainers

    Benzinga
  39. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 ...

    Benzinga
  40. LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes

    Benzinga
Trading Center